Delving into the Latest Updates on GB002, Inc. with Synapse

概览

关联

1

项与 GB002, Inc. 相关的药物

Seralutinib

靶点

CSF-1R x PDGFRα x PDGFRβ x c-Kit

作用机制

CSF-1R拮抗剂 [+3]

在研机构

Gossamer Bio, Inc.

原研机构

Gilead Sciences, Inc.

在研适应症

肺动脉高压

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

4

项与 GB002, Inc. 相关的临床试验

NCT04816604 / Recruiting临床2期

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

开始日期2021-04-05

申办/合作机构

GB002, Inc.

NCT04456998 / Completed临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.

开始日期2020-11-12

申办/合作机构

GB002, Inc.

NCT03926793 / Completed临床1期

A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB002 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)

This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).

开始日期2020-02-04

申办/合作机构

GB002, Inc.

100 项与 GB002, Inc. 相关的临床结果

登录后查看更多信息

0 项与 GB002, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 GB002, Inc. 相关的药物交易

登录后查看更多信息

100 项与 GB002, Inc. 相关的转化医学

登录后查看更多信息